Asahi Kasei consolidates pharmaceutical units under Asahi Kasei Therapeutics
- Target net sales of ¥300 billion by FY2030.
- Approximately ¥40 billion planned for in-licensing over three years.
- Key acquisitions: Veloxis (2020), Calliditas (2024), Aicuris (2026).
- ENVARSUS XR U.S. sales CAGR ~20% since 2020; TARPEYO expected to outperform Calliditas-era projections; Prevymis yields a consistent royalty stream.
Integration
Asahi Kasei will bring Asahi Kasei Therapeutics in Japan, Veloxis Pharmaceuticals in the U.S., Calliditas Therapeutics in Sweden and AiCuris Anti-infective Cures in Germany together under the Asahi Kasei Therapeutics brand, creating a unified global management structure for its pharmaceutical business.
Strategic focus
The group is concentrating on niche specialty therapeutic areas—immunology, nephrology, transplantation and infectious diseases—using focused clinical development and targeted commercial approaches to address unmet medical needs and enable continued investment in development.
Growth drivers
Past acquisitions established commercial and development presence across the U.S. and Europe: Veloxis (2020) for kidney transplantation, Calliditas (2024) to expand into kidney disease and U.S. commercial capabilities, and Aicuris (2026) to extend the infectious-disease pipeline. The combined portfolio includes products and royalties such as ENVARSUS XR, TARPEYO and Prevymis that underpin near-term growth.
Financial targets and investment
Under its medium-term plan, the company aims for net sales of ¥300 billion by FY2030 and plans approximately ¥40 billion of in-licensing investment over three years, alongside continued investment in the existing portfolio, pipeline and potential further M&A and in-licensing opportunities.
Source: Asahi Kasei